



The Commission's work on COVID-19 vaccination and the key role of health professionals


John-F Ryan, Director, Public Health, Directorate-General for Health and Food Safety,
European Commission

EU Health Policy Platform webinar: COVID-19 vaccination. What you need to know as a
health professional. Wednesday 10 February 2021, 11.00-13.00 CET, Brussels time

COVID-19 vaccination in EU Member States- 1

- European Vaccination Days 27-29 December 2020: kick-off of vaccination in Member States
- Focus on priority groups, e.g. older persons and health professionals
- Mid-February 2021: Vaccination continues, but Member States need to **speed up**.

COVID-19 vaccination in EU Member States - 2



COVID-19 vaccination in EU Member States - 3

- Overall targets:
 - By March 2021: Member States to have vaccinated $\geq 80\%$ of health and social care assistants and people over 80 years old
 - By summer 2021, Member States to have vaccinated $\geq 70\%$ of adult population
- **Ambitious** but **reachable**

https://ec.europa.eu/info/sites/info/files/communication-united-front-beat-covid-19_en.pdf

EU Strategy for COVID-19 vaccines - 1

- Commission communication of 17 June 2020
- Secure access to safe and efficient COVID-19 vaccines for EU Member States as soon as they become available
- On the basis of Advance Purchase Agreements: The Commission supports vaccine manufacturers to face upfront costs and has, in return, the right to purchase vaccines once available.
- Financial instrument: The Emergency Support Instrument (ESI)

<https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1597339415327&uri=CELEX:52020DC0245>

EU Strategy for COVID-19 vaccines - 2

- [AstraZeneca](#): 400 million doses **AUTHORIZED**
- [Sanofi-GSK](#): 300 million doses
- [Johnson & Johnson](#): 400 million doses
- [BioNTech-Pfizer](#): 600 million doses **AUTHORIZED**
- [CureVac](#): 405 million doses
- [Moderna](#): 160 million doses **AUTHORIZED**
- Exploratory talks concluded with [Novavax](#) and [Valneva](#)
- In total: up to **2.3 billion** vaccine doses secured

The key role of health professionals

- Health professionals are:
 - administrators of vaccines
 - trusted sources of information
 - role models.
- Health professionals can support COVID-19 vaccination in Member States.

Safety and efficacy of COVID-19 vaccines

- All vaccines go through a strict assessment and authorisation procedure.
- Scientific assessment by the European Medicines Agency
- Marketing authorisation by the European Commission
- COVID-19 vaccines: **conditional** marketing authorisation

High efficacy in robust clinical trials

- Efficacy ranging from 60 % to 95 %
- Size of the clinical trials: from around 10 000 to 40 000 patients
- Calculated on the number of people developing COVID-19 symptoms after injection of the vaccines or dummy injection
- Companies will continue to monitor patients and provide results of the trials (conditional marketing authorisation)

High safety in robust clinical trials

- Assessed on the basis of robust clinical trials data
- Patients continue to be monitored post authorisation
- Additional data collection for safety monitoring foreseen

Today's EU Health Policy Platform webinar

- Safety aspects of COVID-19 vaccination – Dr Fergus Sweeney and Dr Peter Arlett – European Medicines Agency (EMA)
- The impact of COVID-19 vaccination on societies – Dr Edoardo Colzani – European Centre for Disease Prevention and Control
- Opportunity to ask questions/ share concerns.

The Coalition for Vaccination

- European health professionals and students' associations
- Set up in 2019 – first of its kind in Europe
- Advocacy for vaccination
- Co-chaired by the Standing Committee of European Doctors (CPME), the European Federation of Nurses Associations (EFN) and the Pharmaceutical Group of the European Union (PGEU)
- Dedicated space on the EU Health Policy Platform
- Manifesto to encourage health professionals to get vaccinated against COVID-19

Thank you



© European Union 2020

Unless otherwise noted the reuse of this presentation is authorised under the [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/) license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

Slide xx: [element concerned](#), source: [e.g. Fotolia.com](#); Slide xx: [element concerned](#), source: [e.g. iStock.com](#)

